Immuno-Oncology | Specialty

Immunotherapy Combinations Coming to the Forefront in Melanoma

April 7th 2016

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Immunotherapy Agents Could Impact All Settings in NSCLC

April 7th 2016

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

Targeted Immunotherapy on Horizon for Brain Tumors

April 6th 2016

The future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Checkpoint Inhibition New Mainstay in Metastatic RCC

April 6th 2016

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Expert Explains Key Considerations With Immunotherapy in Melanoma

April 5th 2016

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaâ€â€

Immunotherapy Agents Preferred Second Choice in NSCLC, But Questions Remain

April 5th 2016

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

CHMP Recommends Approval of Nivolumab/Ipilimumab Combo for Melanoma

April 1st 2016

The combination of ipilimumab and nivolumab has received a positive recommendation from the CHMP, which suggests that the treatment is likely to gain European approval for patients with advanced melanoma.

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

March 31st 2016

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

EMA Action Brings Nivolumab Closer to First Hematology Approval

March 31st 2016

The European Medicines Agency validated an application for use of nivolumab (Opdivo) for previously treated patients with classical Hodgkin lymphoma), which officially begins the centralized review process for final approval of the drug in the European Union.

TILs Advancing as Melanoma Immunotherapy Option

March 31st 2016

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

The Future of Sarcoma: Nanotechnology, Immunotherapy, and Shark Research

March 29th 2016

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

The Future of Immunotherapy in Myeloma

March 29th 2016

On the Horizon for Multiple Myeloma

March 29th 2016

Antibodies in Combination Therapy for Myeloma

March 29th 2016

Immunotherapy Patient Selection in Myeloma

March 29th 2016

Goals of Therapy in Multiple Myeloma

March 29th 2016

Practical Advice on the Treatment of Multiple Myeloma

March 29th 2016

Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016